ipqc for parenterals

81
1

Upload: ceutics1315

Post on 10-Jul-2015

1.090 views

Category:

Documents


17 download

TRANSCRIPT

Page 1: Ipqc for parenterals

1

Page 2: Ipqc for parenterals

CONTENTS

Introduction to parenterals

What is IPQC

Importance of IPQC and test performed

IPQC tests for parenterals

Documentation of parenterals

Problems encountered and remedies

Page 3: Ipqc for parenterals

A parenteral dosage form can be defined as a sterile drug product which is

presented in the form of solution, suspension, emulsion, or reconstituted

lyophilized powder, suitable for administration by injection through skin or

mucous membrane.

Para enteron = beside the intestine.

PARENTERALS

Page 4: Ipqc for parenterals

Market survey Projected sales

Planning and

Scheduling functions

personnel Documentation Equipment and

control facilities management

Material management

Preparation of facilities

Purchasing

Preparation equipment and packaging components

Manufacturing of small volume parenterals

Page 5: Ipqc for parenterals

Manufacturing of products

Sterilization of products

Aseptic subdivision and sealing

Online testing

Capping/ outer sealing

Inspection

Quarantine

Finishing, labeling and packaging

warehouse

Market

Page 6: Ipqc for parenterals

QC is part of GMP which is concerned with sampling, specification,

Testing and with the organization, documentation and release procedures which

ensures that the necessary and relevant tests are actually carried out and the

materials are not released for sale or supply until their quality has been judged to

be satisfactory

According to ISO 9000:

The operational techniques and activities that are used to fulfil the

requirements for quality.

QUALITY CONTROL

According to WHO

Quality itself has been defined as fundamentally relational: 'Quality is

the ongoing process of building and sustaining relationships by

assessing, anticipating, and fulfilling stated and implied needs.'

Page 7: Ipqc for parenterals

IPQC means controlling the procedures involved in manufacturing of the

dosage forms starting from raw materials purchase to dispatch of the quality

product in ideal packaging.

It monitors all the features of the product that may effect its quality and

prevents errors during processing.

It is the activity performed between QA and QC.

IN PROCESS QUALITY CONTROL

PURPOSE OF IPQC

To ensure detectable and significant human errors.

Equipment failure and idiosyncrasies.

Abnormal interpretation.

Adoption of given procedures.

Page 8: Ipqc for parenterals

To minimize human errors.

Provides accurate, specific, and definite description of the procedure to be

employed.

It is planned system to identify materials and equipment's processed and

operated.

Used to detect errors if and when it does occur.

Is to enforce the flow of manufacturing and packaging operations according

to established routes and practice.

Importance of IPQC

These are the tests performed between QA and QC and provides for the

authorization of approved raw materials for manufacturing based on

actual laboratory testing generally called as IPQC such as physical,

chemical, microbiologic and biologic tests.

IPQC TESTS

Page 9: Ipqc for parenterals

.

SCOPE

In process quality control are particularly important where a process

may vary with time such as tablet weights, fill volume, head space

gases etc.

TYPES OF IPQC TESTS

Physical and chemical.

Biologic and microbiologic

IPQC Tests

Identity tests

Quality tests

Purity tests

Potency tests

Page 10: Ipqc for parenterals

Identity tests

These tests are qualitative chemical methods used to conform the actual

presence of compound for example color formation, precipitation.

Quality tests

These tests are the physical methods used to measure accurately the

characteristic properties of drug .

For example: Absorbance, refractive index.

Purity tests

Purity tests are designed to estimate the level of all known and significant

impurities and contaminants in the drug substance under evaluation .

For example: Tests for clarity of solutions, Acidity, Alkalinity.

Potency tests

Potency tests are assays that estimate the quantity of an active ingredient

in the drug.

Physical and chemical tests

Page 11: Ipqc for parenterals

Biologic and microbiologic testing

It includes macro and micro biologic assays and tests for safety, toxicity,

pyrogenicity, sterility, antiseptic activity and antimicrobial preservative

effectiveness of tests.

Biologic testing of drugs can be Qualitative / Quantitative in

nature.

It utilizes intact animals , animal preparations, isolated living

tissue.

When are these tests employed

Biologic methods employed in the following situations

When adequate chemical assay has not been devised for drug substances

although its chemical structure has been established.

For example: Insulin

When chemical structure of drug substance has not been fully elucidated.

For example: Parathyroid hormone.

When drug is composed of substances of varying structure and activity

For example: Digitalis and posterior pituitary hormone.

Page 12: Ipqc for parenterals

IPQC for parenteral products

Clarity test( for particulate matter )

By visual method

Coulter counter method

Light obscuration technique

Leakage testing( package integrity)

Visual methods

Bubble test

Dye test

Vacuum ionization method

For fill volume

pH

Pyrogen testing

Rabbit fever response test

Limulus amoebocyte lysate test

Assay for drug content

Page 13: Ipqc for parenterals

Sterility test

Membrane filtration method

Direct inoculation method

Test for packing containers

For glass containers

Water attack test

Powder glass test

For plastic containers

Leakage test, collapsibility test, transparency test, water vapor

permeability test.

Inspecting for label check

Uniformity of contents

Uniformity of weight.

Passiability of parenteral preparation from needle

Conductivity test

Page 14: Ipqc for parenterals

CLARITY TESTING (DETECTION OF PARTICULATE MATTER)

Particulate matter can be detected in parenteral product by two methods,

including visual inspection and electronic particulate counting.

A) Visual method

In visual inspection, each injectable is inspected visually against white and

black backgrounds. The white background aids in detection of dark

colored particles.

The light or reflective particles will appear against the black back ground.

Some visual-enhancing aids can increase the efficiency.

A magnifying lens at 2.5 × magnification set at the eye level facilitates the

inspection. Microscopic examination enhances detection of particulate

matter in injectable. Visual inspection gives the qualitative estimation of

the particulate matter.

Acceptance Standards is that each container checked must not contain

any visible particulate matter.

Page 15: Ipqc for parenterals

B) Automated techniques

The automatic systems are also called as the electron particles counter.

the electronic particles counter evaluates the particles in injectables

automatically.

However, this method requires destruction of the ampoule/container for

the particle examination.

Electronic particles counting may be based on any one of the following

principles: a) change in electrical resistance, b) light blockages principle

and c) light scattering. Some of the automated systems for visual particle

inspection include Autoskan, Eisai Ampoule inspection machine, Schering

PDS/A-V system, etc. Autoskan System.

The Autoskan system is based on light scattering principle whereby the

particle in the path of a light source causes the scattering of light. The

scattered light is measured and provides the corresponding information

regarding the presence of particulate in the sample. This is a non-

destructive test.

Page 16: Ipqc for parenterals

Coulter counter technique

Coulter Counter counts the particles in a sample based on the change in the

electrical resistance. Particle size detection limit in this instrument is from 0.1 to

1000 micrometer.

The powder sample requires pretreatment such as dispersion in an electrolyte to

form a very dilute suspension.

The Suspension is usually subjected to ultrasonic agitation to avoid particle

agglomerates.

Based on change in the electrical resistance

A dispersant may also be added to aid particle deagglomeration. Passage of

particle causes the change in electrical resistance in between the electrodes

which is proportional to the volume of particle.

The change in resistance is converted into voltage pulse which is amplified and

processed electronically and split into the particle size distribution into many

different size-range.

This is a destructive test and large errors in measuring flakes and fibers are

expected.

This test is not recommended by FDA for parenteral.

Page 17: Ipqc for parenterals

Principle of light obscuration

Tungsten lamp produces a constant collimated beam of light that pass

through a small rectangular passageway and impinges onto a

photodiode.

Liquid can flow through the passageway between the light source and

photodiode.

If a single particle transverses the light beam there results a reduction in

normal amount of light received by the photodiode .

This reduction of light and the measurable decrease in the output from

the photodiode is proportional to the area of the particle interrupting the

light flow

Thus light obscuration principle measures particle size based on

diameter of circle having equivalent area.

Page 18: Ipqc for parenterals

Test method

Use a suitable apparatus based on the principle of light blockage

which allows an automatic determination of the size of particles and

the number of particles according to size.

Method

Mix the contents of the sample by slowly inverting the container 20

times successively.

If necessary, cautiously remove the sealing closure. Clean the outer

surfaces of the container opening using a jet of particle-free water and

remove the closure, avoiding any contamination of the contents.

Eliminate gas bubbles by appropriate measures such as allowing to

stand for 2 min or Sonicate.

For large-volume parenterals, single units are tested.

Page 19: Ipqc for parenterals

the test solution may be prepared by mixing the contents of a suitable

number of vials and diluting to 25 ml with particle-free water or with an

appropriate particle-free solvent when particle-free water is not suitable.

Small volume parenterals having a volume of 25 ml or more may be

tested individually.

Remove three each of not less than 5 ml, and count the number of

particles equal to or greater than 10 μm and 25 μm.

Disregard the result obtained for the first portion, and calculate the mean

number of particles for the preparation to be examined.

For small-volume parenterals less than 25 ml in volume, the contents

of 10 or more units is combined in a cleaned container to obtain a

volume of not less than 25 ml;

Then 3 aliquots are prepared with about 5 ml sample and injected

into the sensor.

Page 20: Ipqc for parenterals

Principle of light scattering

When a beam of light strikes a solid object three events occur some of the

light is absorbed some is transmitted rest is scattered.

Scattered light is composite of diffracted, reflected, refracted light.

Particle counters that operate on the basis of light scattering are designed

to measure the intensity of light scattered at fixed angles to the direction of

the light beam.

As the liquid flows into a light sensing zone particles in the fluid scatter light

in all directions.

The scattered light is directed onto system of elliptical mirrors that then

focus the light onto a photo detector.

The photo detector converts the signals corresponding area/volume

diameter of the particle.

Page 21: Ipqc for parenterals

Acceptance criteria

As per USP LVP : NMT 50 particles/ ml (size 10 or more than 10

micrometer) & 5 particles/ ml (size more than 25 micrometer)

SVP: 10,000 particles/ container of size 10 micrometer or greater &

NMT 1000 particles/ container greater than 25 micrometer.

Page 22: Ipqc for parenterals

Leakage test

Leakage test is employed to test the package integrity. Package integrity

reflects its ability to keep the product in and to keep potential

contamination out.

It is because leakage occurs when a discontinuity exists in the wall of a

package that can allow the passage of gas under pressure or

concentration differential existing across the wall.

leak test methods.A) VISUAL INSPECTION

Visual inspection is the easiest leak test method to perform. But this method is

least sensitive..

The method is used for the evaluation of large volume parenteral. To increase

the sensitivity of the method, the visual inspection of the sample container may

be coupled with the application of vacuum to make leakage more readily

observable.

This method is simple and inexpensive. However, the method is insensitive,

operator dependent, and qualitative.

Sometimes, the method is used in combination with pressure and /or

temperature cycling to accelerate leakage to improve sensitivity.

Page 23: Ipqc for parenterals

B) BUBBLE TEST

The test package is submerged in liquids. A differential pressure is

applied on the container. The container is observed for bubbles.

Sometimes, surfactant added liquid is used for immersion of test

package. Any leakage is evident after the application of differential

pressure as the generation of foaming in immersion liquid. The method is

simple and inexpensive.

The location of the leaks can be observed in this method. However, it is

relatively insensitive and the findings are operator dependent and are

qualitative.

The optimized conditions can be achieved using a surfactant immersion

fluid along with the dark background and High intensity lighting.

Generation of a differential positive pressure of 3 psi inside the vial and

observation of any leakage using magnifying glass within a maximum test

time of 15 minutes.

Positive leak test result. Air bubbles

Page 24: Ipqc for parenterals

C) DYE TESTS

The test container is immersed in a dye bath. Vacuum and pressure is

applied for some time.

The container is removed from the dye bath and washed. The container

is then inspected for the presence of dye either visually or by means of

UV spectroscopy.

The dye used may be of blue, green, yellowish-green color.

The dye test can be optimized by use of a surfactant and or a low

viscosity fluid in the dye solution to increase the capillary migration

through the pores.

The dye test is widely accepted in industry and is approved in drug use.

The test is inexpensive and is requires no special equipment required

for visual dye detection.

However, the test is qualitative, destructive and slow. The test is used

for ampoules and vials.

Page 25: Ipqc for parenterals

D) VACUUM IONIZATION TEST

Vacuum ionization test is useful for testing leakage in the vials or bottles sealed

under vacuum.

This test is used for online testing of the lyophilized products. High voltage, high

frequency field is applied to vials which to cause residual gas, if present to glow.

Glow intensity is the function of headspace vacuum level.

The blue glow is the indicative of vacuum which indicates the absence of leak

while the purple glow indicative of no vacuum. The sensitivity of the method is

not documented. This test is on-line, rapid and is non destructive test.

However, the proteins present in the test sample may be decomposed. This

method is used for the lyophilized vials of biopharmaceuticals.

528 × 904 - Leak Test Vacuum Systems

Page 26: Ipqc for parenterals

Check for fill volume

After filling the containers they are checked for the

correct volume filling.

Check for fill volume is by visual inspection.

This is important for small volume parenterals where the volume

is less .

By keeping the container against a bright background we can

check for the fill volume.

After conforming for the correct fill volume then they are lacked

and labelled and sent to the ware house.

Page 27: Ipqc for parenterals

pH

Checking the bulk solution, before filling for drug content,

pH, color, clarity and completeness of solution

The pH of a formulation must be considered from following standpoint:

1) the effect on the body when the solution is administered

2) the effect on stability of the product

3) the effect on container-closure system

pH measurement

pH is measured by using a pH meter .

pH meter is initially calibrated with respective buffer capsule then the pH

of the preparation is measured.

Page 28: Ipqc for parenterals

What are pyrogens

The term pyrogen frequently refers to gram negative bacterial endotoxin.

Pyrogen is a general term for any substance that causes fever after IV

administration / inhalation .

Microbial substances which act as pyrogen includes bacteria , fungi ,

plasmodia , viruses, staphylococcal endotoxin.

The amount of USP reference standard endotoxin needed to initiate

pyrogenicity in humans and rabbits is about 1ng/kg.

Naturally occurring bacterial endotoxin contain the lipid, carbohydrate and

protein makeup of the outer cell membrane of gram negative bacteria.

Page 29: Ipqc for parenterals

Test for pyrogens can be carried out by in-vitro and in-vivo methods.

A) Rabbit test (in-vivo)

B) LAL test (Limulus amoebocyte lysate) (in-vitro)

A)RABBIT TEST:

Principle:

The test involves measurement of rise in body temperature of the rabbits following

the intravenous injection of a sterile solution of the substance to be tested.

The body temperature of the rabbits increases if pyrogens are present in the

injected test solution.

SELECTION OF TEST ANIMALS:

Healthy , adult rabbits of either sex, each weighing not less than 1.5kg.

Do not use any rabbit for main test if:

1) It shows a temperature variation greater than 0.20 c between two successive

readings noted during the determination of initial temperature .

2) And it’s temperature is higher than 39.80 c or lower than 380 c

Page 30: Ipqc for parenterals

EQUIPMENTS REQUIRED FOR THE TEST:

All glass ware, syringes, 20 – 30 gauge needle is used and thermometer

must be thoroughly washed with water for injection and heated in a hot air

oven at 2500c for NLT 30 min.

Retaining boxes for rabbits.

TEST:

The test is carried out on a group of three rabbits.

Procedure:

Preparation of the sample:

Warm the solution to About 37 ± 2 o c before the injection. In the case of

lyophilized products dissolve it in normal saline solution.

Determination of initial temperature of rabbits:

Insert a clinical thermometer into the rectum of each rabbit and normal readings of

body temperature are taken prior to the injection of test solution.

Two such readings are taken at an interval of 30 minutes and the mean is

calculated.

This mean reading is taken as the initial temperature of the rabbits or as a control.

Page 31: Ipqc for parenterals

Temperature recording

USP <85> states the following:

Use accurate temperature sensing device such as clinical thermometer,

or thermistor probes or similar probes that have calibrated to assure an

accuracy of ±0.10c.

Insert the temperature sensing probe into the rectum of the test rabbit to a

depth of not less than 7.5 cm .

Thermocouple contains two dissimilar electric conductor wires joined at

one end to form measuring junction that produce thermal EMF.

Thermocouples must be calibrated against National institute of standards

and technology.

Page 32: Ipqc for parenterals

Determination of the response of rabbits:

The test solution is injected into the ear vein of each rabbit.

The volume of injection is 10 ml/kg of the body weight.

This volume varies according to the test substance and is prescribed

in the individual monograph.

Record the temperature of each rabbit at an interval of 30 minutes for

3 hours after the injection.

This is the maximum temperature recorded for that rabbit.

The difference between maximum temperature and initial temperature

is taken as its response.

If this difference is negative, it is taken as a zero response.

Page 33: Ipqc for parenterals

Interpretation of the results

Consider any temperature decrease as zero rise. If no rabbit shows an

individual rise in temperature of 0.5 0 c / more above its respective control

temperature , the product meets the requirements for absence of pyrogens.

If any rabbit shows an individual temperature rise of 0.5 0c or more

continue test using five other rabbits .

If not more than three of eight rabbits show individual rise in temperature of

0.5 0c / more if sum of eight individual maximum temperature does not

exceed 3.3 0c the material under examination meets the requirement for

absence of pyrogens.

Page 34: Ipqc for parenterals

Limitations of rabbit pyrogen test

In vivo model

A test method that uses a living animal as model will suffer from number

of problems offered by biological systems.

No two rabbits will possess exactly the same body temperature or

respond identically to same pyrogenic sample.

Rabbits are sensitive and vulnerable to their environment.

Rabbit sensitivity to pyrogens

The pyrogenic response in rabbits is dose dependent.

The greater the amount of pyrogen injected per kilogram body weight

the greater the temperature increase in rabbits.

The rabbit test is less sensitive to endotoxin.

It reports 50% pass/fail rate with 95% confidence at endotoxin level

above 0.098ng/m (9/10ml/kg) dose

The greatest rise in temperature for any given dose of endotoxin

occurred in the afternoon , while the least raise occurred at midnight.

Page 35: Ipqc for parenterals

Interferences of the rabbit pyrogen tests

Many products administered parenteral cannot be tested for pyrogens

with the rabbit test because of the interferences they create in the rabbit

response to pyrogens if they are present in the product

Any products having a pyretic side effect such as the prostaglandins and

the cancer chemotherauptic agents will interfere with rabbit response.

Page 36: Ipqc for parenterals

Reaction mechanism Endotoxin or a suitably prepared lipid A derivative of endotoxin activates

a proenzyme of LAL having a molecular weight of 150,000.

Activation also depends on the presence of divalent metal cations such

as calcium, manganese or magnesium. It has been shown that the

sensitivity of the LAL assay for endotoxin detection can be increased 10

to 30 times by using LAL reagent containing 50mM magnesium.

The activated proenzyme related to the serine protease class containing

such enzymes as thrombin, trypsin and factor 10a subsequently with a

lower molecular weight protein fraction (MW=19000-25000) contained

also in the LAL substance.

The lower molecular fraction called coagulogen is cleaved into soluble

and insoluble subunit .The insoluble subunit appears as a solid clot , or

a turbid solution depending on coagulogen.

LIMULUS AMOEBOCYTE LYSATE TEST(LAL)

In this test the presence of endotoxin is detected by formation of solid gel.

Page 37: Ipqc for parenterals

Horseshoe crabs are placed in a

restraining rack and

passively bled for a few minutes. They are

promptly returned

to the sea unharmed. Amebocyte blood

cells are concentrated,

washed, and lysed to produce LAL

reagent.

Page 38: Ipqc for parenterals

Gel clot bacterial endotoxin test

The gel clot end point is the most commonly used endotoxin test

It is simple and requires minimal laboratory equipment

Equal volumes of test solution and LAL reagent ( usually 0.1 ml of each) are

mixed in glass test tubes .

After incubation at 37 degrees c for one hour tubes are observed for clot

formation after inverting them.

Formation of solid gel clot that withstands inversion of the tube constitutes a

positive test.

Each lot of gel clot reagent licensed by the FDA must be labeled with

sensitivity( lambda) to reference standard endotoxin(RSE).

Page 39: Ipqc for parenterals

Kinetic turbidimetric assay

During LAL endotoxin reaction the solution mixture becomes increasingly

turbid

The kinetic turbidimetric assay (KTA) requires the incubating micro plate or

tube reader driven by an endotoxin specific software.

The reaction mixture in a KTA system are continuously monitored for

changes in optical density in each sample that are caused by scattering

and absorption of light.

Generally the KTA measures the onset time needed to reach a

predetermined absorbance by each reaction mixture .

The onset times for sample are compared with those of endotoxin studies

to yield quantitative values for each sample / control that contain endotoxin

Page 40: Ipqc for parenterals

Kinetic and endpoint chromogenic assay

Chromogenic LAL test do not utilize the coagulogen proteins from LAL

reagent to produce an endpoint

Although endotoxin activates the same enzymatic cascade from the

reagent as described above the clotting enzyme reacts with synthetic

substrate that has been added to the reaction mixture.

The substrate consists of a colorless amino acid chain attached to a

chromophore.

The activated clotting enzyme cleaves the bond that holds the

chromophore to the amino acid.

The amount released is proportion to the concentration of endotoxin

The chromophore that is released changes the color of the reaction mixture

thereby increasing the optical density

After reaction is determined the absorbance is read over one log range.

Page 41: Ipqc for parenterals
Page 42: Ipqc for parenterals

Advantages compared to the rabbit test

Proponents of the LAL test claim that the test offers at least seven

advantages over the rabbit test for detecting pyrogens .

Greater sensitivity

Greater reliability

Better specificity

Less variation

Wider application

Use as a problem solving tool

Less expense.

Researchers summarized the superiority of LAL test over the rabbit test

by following:

After tens of thousands of tests an unexplained negative LAL test result –

rabbit positive test result was never recorded.

Sometimes the rabbit test initially fails to detect pyrogens that were

sometimes confirmed by initial LAL tests.

Page 43: Ipqc for parenterals

Limitations of the LAL tests

The greatest limitation of the LAL test is the problem of interference of

the lysate –endotoxin interaction that is caused by a variety of drugs and

other substances

The reaction is mediated by clotting enzyme that is heat labile, pH

sensitive and chemically related to Trypsin .

Inhibition caused by any material known to denature protein or to inhibit

enzyme action .

Inhibition can be overcome by dilution or pH adjustment.

Dilution reduces the concentration of endotoxin and places greater

demand on the sensitivity of the LAL regent to detect diluted amounts of

endotoxin.

LAL test applications

Used in atleast six different areas

pharmaceuticals, biologics, devices, disease states, food, validation of

dry heat cycles.

Page 44: Ipqc for parenterals

Assay

Assay is performed according to method given In the monograph

of that parental preparation in the pharmacopeia

Assay is done to check the quantity of medicament present in the

parenteral preparation.

So we can know the exact amount of medicament present such that it

can perform its action.

We should follow the official monograph IP/BP/USP for performing the

assay.

Page 45: Ipqc for parenterals

Sterility test

It is done for detecting the presence of viable forms of bacteria, fungi and

yeast in parenteral products.

The test for Sterility must be carried out under strict aseptic conditions in

order to avoid accidental contamination of the product during test.

All glassware's required for the test must be Sterile.

Sterility testing attempts to reveal the presence or absence of viable micro-

organisms in a sample number of containers taken from batch of product.

Based on results obtained from testing the sample a decision is made as to

the sterility of the batch.

Sterility can be defined as the freedom from the presence of

viable microorganisms.

Page 46: Ipqc for parenterals

Major factors of importance in sterility testing :

The environment in which the test is conducted

The quality of the culture conditions provided

The test method

The sample size

The sampling procedure

Environmental conditions :

Environmental conditions avoid accidental contamination of the

product during the test.

The test is carried out under aseptic conditions regular microbiological

monitoring should be carried out .

Culture conditions :

Appropriate conditions for the growth of any surviving organism should

be provided by the culture media selection.

Page 47: Ipqc for parenterals

Factors affecting growth of bacteria :

Nutrition

Moisture

Air

Temperature

pH

Light

Osmotic pressure

Growth inhibitors

Culture media used for sterility testing:

Fluid thioglycolate medium

Soybean casein digest medium

Page 48: Ipqc for parenterals

Fluid thioglycolate medium(FTM):

FTM provides both aerobic and anaerobic environments within the same

medium.FTM is an excellent medium for the detection of bacterial

contamination.

Thioglycolate has the advantage of neutralizing the bacteriostatic

properties of mercurial preservatives.

COMPOSITION :

L-cysteine , trypticase peptone, dextrose , yeast extract, sodium

chloride, sodium thioglycolate,resazurin,agar,purified water ,final pH 7.1

specific role of some ingredients primarily intended for

the culture of anaerobic bacteria.

incubation of the media: 14 days at 30 -35°C

Page 49: Ipqc for parenterals

Soybean casein digest medium:

Soya-bean casein digest medium primarily intended for the culture of both fungi

and aerobic bacteria specific role of some ingredients.

incubation of the media: 14 days at 20 -25°C

COMPOSITION

Trypticase soya broth, trypticase peptone, phytone peptone, sodium chloride ,

dipotassium phosphate, dextrose, purified water , final pH 7.3

Sterility test methods

Direct inoculation method

Membrane filtration method.

Membrane filtration methods

Selection of filters for membrane filtration :

pore size of 0.45µ effectiveness established in the retention of micro-

organisms appropriate composition the size of filter discs is about 50 mm in

diameter

Page 50: Ipqc for parenterals

The procedure of membrane filtration

sterilization of filtration system and membrane filtration of

examined solution under aseptic conditions.

Filtration of the sample through a membrane filter having the

nominal size of 0.45µ and a diameter of 47mm.

After filtration the membrane is removed aseptically from the

metallic holder and divided into two halves.

The first half is transferred into 100 ml of culture media meant for

fungi and incubated at 20˚ to 25 ˚c for not less than seven days.

The other half is transferred into 100ml of fluid thioglycolate

medium and incubated at 30 to 35 ˚c for not less than 7 days.

Page 51: Ipqc for parenterals

Advantages of membrane filtration over direct inoculation method

Greater sensitivity

The entire contents can be tested providing an advantage in the sterility

testing of LVP and increasing the ability to detect contamination.

The antimicrobial agent and antimicrobial solutes in the product sample can

be eliminated by rinsing prior transferring the filter into test tubes of media

thereby minimizing the incidence of false-negative test results.

Organisms present in an oleaginous product can be separated from the

product during filtration and cultured in a more desirable aqueous medium.

Disadvantages

This method cannot differentiate the extent of contamination between units

if present because all product contents are combined and filtered through a

single filter and cultured in single test tube.

There exists a higher probability of inadvertent contamination in manual

operations .

Page 52: Ipqc for parenterals

Samples size to be taken

Number of articles in

batch (injectables)

Number of articles to be

tested

Not more than 100 articles 10%/ 4 articles whichever is

greater

More than 100 but not more

than 500

10 articles

For more than 500 2%/ 20 articles whichever is

less

For large volume

parenterals

2%/10 containers whichever

is less.

Page 53: Ipqc for parenterals

Direct inoculation method

Required quantities of liquid is removed from the test containers with a

sterile pipette / sterile syringe.

Aseptically transfer the specified volume of the material from each

container to vessel of culture medium

Mix the liquid with medium but not aerate excessively

Incubate the inoculated media for not less than 14 days , unless otherwise

specified in the monograph at 300c - 350c in the case of fluid thioglycolate

medium and 200c - 250 c for soybean casein digest medium.

When materials examined renders the medium turbid so presence /

absence of microbial growth cannot be determined readily by visual

examination transfer suitable portions of medium to fresh vessels of the

same medium between 3 rd. and 7 th day after test is started.

Continue incubation of the transfer vessel for not less than 7 additional

days after transfer and total of NLT 14 days.

Page 54: Ipqc for parenterals

Interpretation of results

At the end of the incubation period the following observations are possible:

No evidence of growth; hence the preparation being examined passes the test

for sterility.

If there is evidence of growth, retesting is performed using the same number of

samples, volumes to be tested and the media as in the original test. If no

evidence of microbial growth is then found, the preparation being examined

passes the test for sterility.

If There is again evidence of the microbial growth then isolate and identify the

organisms. If they are not readily distinguishable from those growing in the

containers of the first test then the preparation being examined fails the test for

sterility.

If they are distinguishable from the organisms of the first test then again do the

test using twice the number of samples. The preparation being examined

passes the test for sterility in case there is no evidence of microbial growth. In

case there is evidence of growth of any micro organisms in second re –test,

the preparation being examined fails the tests for sterility.

Page 55: Ipqc for parenterals

Powdered glass Test: Use crushed glass containers in 250-ml conical flask, add 50 ml high purity

water, cap the flask with borosilicate glass beaker

Place the containers in the autoclave and close it securely hold temperature at

1210c±20c for 30 min., counting from the time this temperature is reached.

cool the flask, decant the water from the flask into a clean vessel, and wash the

residual powdered glass with high purity water, add 5 drops methyl red solution,

titrate immediately with 0.02 N sulfuric acid .

Record the volume of 0.02N Sulfuric acid used to neutralize the extract from 10

g of the prepared specimen of glass.

Test for packaging containers

Type Type of

test

Size

(ml)

ml of

0.02N

H2SO4

ˡ Powder

glass

All 1.0

ˡˡ Water

attack

100/less

Over

100

0.7

0.2

ˡˡˡ Powder

glass

All 8.5

Non

parenter

al

Powder

glass

All 15.0

Water attack at 121°C Rinse 3 or more containers with high purity

water.

Fill each container to 90% of its capacity with

high purity water.

Cap all the flasks with borosilicate glass

beaker, place in the autoclave at 121 C for 60

min

Page 56: Ipqc for parenterals

Test for plastics

Leakage test

10 containers are filled with the parenteral fluid and inverted

for 24 hrs. and checked for any leakage.

Transparency

Dilute the preparations and compare the cloudiness with the control that is

water.

Water vapor permeability

Containers stored at 20-25o c at 60±5% Rh for 14 days and check for water

vapor permeability.

Rubber closure tests

Sterilization

Fragmentation

Self sealability

Clarity and color

Page 57: Ipqc for parenterals

Labels and labeling

The label states the name of the preparation (in case of a

liquid preparation)

The percentage content of drug in a specified volume (in

case of dry preparation)

The route of administration

Storage condition

Expiration date

Name of the manufacturer

The lot number

Containers for injection that are intended for use as dialysis, or

irrigation solution are labeled to indicate that the contents are not

intended for use by iv infusion

Injection intended for veterinary use are labeled to that effect

The containers are so labeled that a sufficient area of the container

remains uncovered for its full length to permit inspection of the

contents

Page 58: Ipqc for parenterals

UNIFORMITY OF CONTENTS:

Unless otherwise stated in the individual monograph, suspensions for injection that are presented in single dose containers and that contain less than 10mg or less than 10 % of active ingredient comply with the following test.

For suspensions for injection containing more than one active ingredient carry out the test for each active ingredient that corresponds to above conditions.

The test for uniformity of contents should be carried out only after the content of active ingredient in a pooled sample of the preparation has been shown to be within accepted limits of the stated content.

Determine the content of active ingredient of each of 10 containers taken at random, using the suitable analytical method of equivalent accuracy and precision.

Page 59: Ipqc for parenterals

The preparation under examination complies with the test if the individual

values thus obtained are all between 85 and 115 % of the average value.

The preparation under examination fails to comply with the test if more

than one individual value is outside the limits 85 to 115% of the average

value or if any one individual value is outside the limits 75 to 125% of the

average value.

If one individual value is outside the limits 85 to 115% but with in the limits

75 to 125% of average value, repeat the determination using another 20

containers taken at random.

The preparation under examination complies with the test if in the total

sample of 30 containers not more than one individual value is outside the

limits 85 to 115% and none is out side the limits 75 to 125% of the average

value.

Page 60: Ipqc for parenterals

UNIFORMITY OF WEIGHT:

For powders for injection that are required to comply with the test for uniformity of content of all active ingredients ,the test for uniformity of weight is not required.

Remove any adherent labels from a container and immediately weigh the container and its contents.

Empty the container as completely as possible by gentle tapping, rinse if necessary with water and then with Ethanol (95%) and dry at 1000 c to 1050 c for 1hr.

If the nature of the container precludes such treatment, dry at a lower temperature to constant weight.Allow to cool in a desiccator and weigh.

The difference between the weights represents the weight of the contents.

Repeat the procedure with a further 19 containers and determine the average weight.

Not more than two of the individual weights deviate from the average weight by

more than 10% and none deviate more than 20%.

Page 61: Ipqc for parenterals

Document is a paper that provides information especially

of an official or legal nature, written report or record.

Documentation is a method of preparing a written material, which

describes the process in terms of specifications, instructions etc.

Documentation and records are essential for obtaining accreditation,

certification of ISOs and approvals by Federal Bodies.

Documentation

Page 62: Ipqc for parenterals

Provide working details necessary for manufacturing,

packaging and QC.

Reduce the risk of mistakes inherent in verbal communication.

Help in tracing the deviation from the expected yields.

Help in decreasing the batch to batch variations so that the quality of product kept within the limit of acceptability.

Considered as history of batch operations.

Self inspection of procedures in order to achieve better control of operations and improvement of product design

Importance Of Documentation of Records

Page 63: Ipqc for parenterals

Particulars with respect to their storage, stability & handling.

Instructions of all manufacturing & packaging procedures, preferably batch wise

are documented so that no further calculations are required at the work of floor

level.

Instructions for non product related operations such as cleaning & disinfections,

maintenance of equipment, monitoring of working conditions use of specific

conditions.

Records such as batch manufacturing record, batch packaging record, test record for

no product related operations as indicate.

Procedures for testing for e.g. physical, chemical, microbiological. Etc. to be followed.

Specifications of starting material packaging materials and product for the

compliance by the quality control department.

Important areas of documentation

Page 64: Ipqc for parenterals

In FDA-speak:

“If it is not

documented . . .

it did not

happen!”

or, it’s a

rumor!”

Document, Document, Document!!!

Page 65: Ipqc for parenterals

OBSERVATION

PAREMETERS

OBSERVATIONS / ACCEPTANCE CRITERIA

Date -

Time Observation should be recorded at an interval of one hour

a)Manufacturing area

General cleanliness Floor, walls, ceiling ,fans, window panels and ledges should be

visibly free from dirt, dust foreign matter.

RH/temperature Note the RH and temperature on the hygrometers

Insect trap/ air curtain-

ON

Should be in operation.

Status label for

All tanks

Jacketed vessels

Other accessories

All manufacturing and storage tanks , jacketed vessels, filter

press, pipes, colloidal mills & other accessories should be

labeled with CLEANED or TO BE CLEANED or product label

with details of product name, mfg. date stage and date of

processing.

Page 66: Ipqc for parenterals

Raw materials other than the

current batch removed

Raw materials only for batch under process should

be required for present and others should be

removed from process area.

All tanks properly covered All manufacturing & storage tanks should be covered

with lids

Status label for

Balance

Sifter

Multi-mill

Blender

Tray drier

Other accessories

All in-process materials

Packaging

Labeling

Segregation

quarantine

RM quality during sifting

Sugar quality after milling

Blend quality

Page 67: Ipqc for parenterals

Packaging area

General cleanliness Floors, walls, ceiling, fans and ledges should be visibly free

from dust and foreign matter.

Insect trap/air curtains-

ON

Should be in operation

Status label present for

Packaging/filling area

Filling machine

ROPP cap sealing

machine

Packaging / filling area, filling machine ,sealing machine

should be labelled with CLEANED or TO BE CLEANED or

product label with details of product name , batch name,

mfg. date stage & date of processing.

Packaging materials

other than that required

for current batch removed

Packaging materials only of the batch under packaging

should be present and others should be removed

Bottle washing

Water sprinkler

Check all the water jets of the bottle washing machine are in

working condition

Washing bottles –check The glass bottles should be free from physical defects. Pour

filtered water into bottles close and check the bottles again

,should be free from particles, fibres.

Page 68: Ipqc for parenterals

Filling tanks

Labelled

Cover present/ absent

Solution level NLT 1/4 of

tank height

Product label with product details must be present

Tanks should be covered during filling process

Solution level should be NLT ¼ of tank height.

ROPP cap

No visual defects

cleanliness

Sealing/threading

Ease of cap opening /re-

sealing

Should be free from damages and monogram should be

uniform and should be in Centre.

Caps should be free from dust and metallic particles

Sealing should be complete threading should be without

cuts.

Should open properly with good bridge cutting and

should reseal properly without over turning.

Leak test

Before seal opening

After re-sealing

Invert the filled ,sealed bottles &keep for 30min .it should

not leak.

Open the cap and reseal ,invert the bottle again and

check for leakage.

Check on filled bottles

Sealing

Volume

Foreign matters and defects

Sealing should be proper without cuts

Check as per BPR

Should be free from foreign matter and glass.

Page 69: Ipqc for parenterals

Coding details

B.No/Mfd./Exp./price

Clarity

Positioning

Check all coding details on labels and cartons and compare

with BPR and signed specimens

Clarity of printing should be free from ink smudges.

Position of coding details should be proper against each

detail.

Labelling

Soiling/smudging

Print clarity

Positioning

Gumming

Labels should be free from soiling and printed matter should be

free from smudging

Printed matter & colors should be uniform shades & clear

Pasting of labels should be proper without cross labelling or

wrinkles.

Should be proper without excess gum

Carton

Printing clarity

Coding details/clarity

Carton erection & closing

Should be of uniform shades and clear

Coding details should be compared with BPR and signed

specimens and be clear & properly positioned

Should be neat and definite with proper bottom. Sides locking.

Closing should seal properly & shouldn't open out

Leaflet Presence of proper literature should be properly checked printing

matter and folding should be proper.

Page 70: Ipqc for parenterals

Measure cup/ dropper

Cleanliness

Free from visual defects

Fixation of cup/dropper

assembly

Should be clean and visually free from any foreign matter

Should be free from dents, scratches, breakage.

Cups should fix to the bottle neck with slight push and

should not fall out when lifted.

Corrugated box –external

Address/position/clarity

Handling cautions/ position

Pack slip

Stapling

Stacking

Should be printed on left bottom side printing should be without

smudges

Should be printed on another length wise portion opp to printing of

address in middle of panel.

Should be pasted with details properly stamped , for trade name

products, with monogram& generics monogram

Good quality rust proof should be used & should be used at 45

deg angle NT 60 mm b/w two stapling.

Should be properly stacked & lower box should withstand the

weight.

Corrugated box internal

Liners & partitions

contents

Liners should be placed properly & formation of partition should

be uniform.

Should comply as per the instructions & quantities to be pkd

Page 71: Ipqc for parenterals

Master formula records

Name of the product________________________________________

Name and Weight of API ____________________________________

Name and Weight of Ingredient _______________________________

Description of equipment ____________________________________

Statement of theoretical yield_________________________________

Process and packaging procedure_____________________________

A description of container____________________________________

closure and packaging material _______________________________

In process control during processing ___________________________

In process control during packaging____________________________

Precaution to be taken______________________________________

Page 72: Ipqc for parenterals

Date Time Incubation

temperature

Humidity in case of

hygroscopic substances’

Plate no duration Location No of colonies

Product_______________________________ lot no._______________

Room____________________ date exposed_____________________

Media__________________________

Environmental control

Page 73: Ipqc for parenterals

Description of containers ___________________________________

Q/C report of container ____________________________________

Date ________________________ Equipment used______________

Cleaning agent used ________________________________________

Cycle of washing: __________________________________________

Sign. Of officer____________________________________________

Preparation of equipment's and containers

Articles Date Time when oven

started

Desired temp

attained

Temperature Time when oven

switched off

If sterilized by dry heat or autoclave

Page 74: Ipqc for parenterals

Equipment's used for filtration ___________________________________

Date__________________________ Time_________________________

Result of test or analysis of solution_______________________________

Equipment used for filling_______________________________________

Date________________________________________________________

Sign. Of officer____________________________________________

Time Filling started Filling completed

Filtration and filling

Page 75: Ipqc for parenterals

Ampoule filling on industrial scale followed by terminal autoclaving

Ampoule filling on small scale

Steps of filling and sealingPowder filling machine in vials and ampoules

Page 76: Ipqc for parenterals

Visual inspection:

Description ___________________

Total no of filled, sealed & sterilized containers rejected ___________

Nature of defects ___________________________________

Name of worker who examined

(i). ________________________________________________

(ii). _______________________________________________

(ii). _______________________________________________

IPQC RECORDS

Page 77: Ipqc for parenterals

Product name_______________________

Batch no_______________________

Strength___________________________

batch size ______________________

Category___________________________

mfg. date _______________________

MFG no_________________________

exp date _______________________

Description of packaging ______________

Pre-coding of labels & printed packaging materials

Examined verified by_____

No. of pre-coded __________________________

Printed packaging material received _____________________

Result of bulk finished products ______________________

Sign. Of officer ___________________________________________

Batch packaging and labeling records

Page 78: Ipqc for parenterals

Problems encountered and their remedies

Problem encountered Remedy

Leakage of ampoules Discard the ampoule

Use new ampoule with

proper sealing

Perforation in filter leading

to defective filtration

Changing the filter

Foreign particles/dust Membrane filtration

Fibres Optical and visual

inspection

pH Use of buffers

Leaching Internal coating of glass

containers.

Page 79: Ipqc for parenterals

Encyclopedia of pharmaceutical technology third edition edited by

James Swabrick volume 5.

Indian pharmacopeia (1996) volume 2

United states pharmacopeia (2000) volume 2

Pharmaceutical dosage forms : parenteral medications volume 3

by Kenneth E Avis; Herbert A Lieberman; Leon Lachman.

The Theory and Practice of Industrial Pharmacy by

Leon Lachman ; Herbert A. Lieberman ; Joseph L. Kanig.

Parenteral Quality Control: Sterility, Pyrogen, Particulate and Package Integrity

Testing

By (author) Michael J. Aker; Revised by Dana Morton Guazzo.

By Daniel S. Larrimore.

References

Page 80: Ipqc for parenterals

IPQC PowerPoint presentation from author stream by Govind Bhandari from Mahakal institute of pharmaceutical studies.

Sterile Dosage Forms I. Parenteral Products by Professor Dr. Nagia Nagib Afifi by German university in Cairo ( GUC).

Pharmaceutical practical guide.

Some PowerPoint presentations from slideshare.

Product management and Documentation by professor of East west college of pharmacy Bangalore.

Page 81: Ipqc for parenterals